VFA
AMLX icon

Values First Advisors’s Amylyx Pharmaceuticals AMLX Stock Holding History

Values First Advisors’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,733
Closed -$50.9K – 174
2023
Q1 		$50.9K Buy
+1,733
New +$60.2K 0.03% 190

Other funds holding AMLX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Values First Advisors's AMLX Position: Q2 2023 in Review

Values First Advisors sold out of Amylyx Pharmaceuticals (AMLX) in Q2 2023, closing a stake of 1,733 shares — an estimated $50.9K sold.

Values First Advisors first reported a position in AMLX in Q1 2023 and held it in 1 quarter. The position peaked at $50.9K in Q1 2023. 154 funds tracked by Wall St. Rank hold AMLX as of Q2 2023.

  • Values First Advisors reported no remaining Amylyx Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Values First Advisors sold 1,733 Amylyx Pharmaceuticals shares in Q2 2023, an estimated $50.9K.
  • Values First Advisors first reported a position in Amylyx Pharmaceuticals in Q1 2023 and held it in 1 quarter.
  • Values First Advisors's Amylyx Pharmaceuticals position peaked at $50.9K in Q1 2023.
  • 154 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2023.

Based on Values First Advisors's 13F filing for Q2 2023, filed 2 Aug 2023.